Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer.

S, Sugawara; JS, Lee; JH, Kang; HR, Kim; N, Inui; T, Hida; KH, Lee; T, Yoshida; H, Tanaka; CT, Yang; M, Nishio; Y, Ohe; T, Tamura; N, Yamamoto; CJ, Yu; H, Akamatsu; Y, Namba; N, Sumiyoshi; K, Nakagawa

doi:10.1016/j.annonc.2021.06.004

Public

Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer.

Shared by NobleBlocks on Jun 15, 2021 • 12:00 AM UTC

Authors:

Sugawara S

Lee JS

Kang JH

Abstract

<h4>Background</h4>This international, randomized, double-blind phase III study (ONO-4538-52/TASUKI-52) evaluated nivolumab with bevacizumab and cytotoxic chemotherapy as first-line treatment for nonsquamous non-small-cell lung cancer (NSCLC).<h4>Patients and methods</h4>Between June 2017 and July 2...

Subject

NSCLC

Bevacizumab

Nivolumab

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!